BALTIMORE--(BUSINESS WIRE)--WellDoc®, a healthcare company that develops technology solutions to improve chronic disease management outcomes and reduce healthcare costs, will showcase its innovative system for diabetes treatment at the American Diabetes Association Annual Meeting (ADA) in San Diego, Calif., June 24-28. The conference brings together 13,000 of the world’s leading diabetes experts for sessions focused on diabetes treatment and research.
During the conference, WellDoc executives will share final results from a randomized controlled clinical trial of the DiabetesManager® System conducted in partnership with the University of Maryland and CareFirst® BlueCross BlueShield of Maryland. The WellDoc DiabetesManager System is a mobile health (mHealth) solution that helps adult patients with type 2 diabetes effectively manage their disease in cooperation with their healthcare provider and reduce health care costs associated with managing chronic disease. It is the only mobile-based system to be clinically validated and cleared by the FDA for real-time patient coaching and clinical decision support for providers and educators.
There will be a number of presentations occurring during ADA where the results from this clinical trial will be discussed:
- Saturday, June 25 from 8:00-10:00 a.m. during a scientific session titled “Technology & Behavior Change Across the Lifespan.”
Speakers include:
- Chair - Shelagh A. Mulvaney, PhD
- Charlene Quinn, PhD, RN, Assistant Professor, Department of Epidemiology and Public Health, University of Maryland School of Medicine
- Michael A. Harris, PhD
- Jean M. Lawrence, ScD, MPH, MSSA
- Lee M. Ritterband, PhD
- Sunday, June 26 at 10:15-11:00 a.m. during a Product Theater session titled, “Mobile Health Technology (mHealth): Transforming Diabetes Care and Improving Outcomes,” sponsored by WellDoc. A demonstration of the virtual patient coach and the provider clinical decision support tools will take place, as well as a discussion of mHealth and sample cases will be presented.
Speakers include:
- Dr. Suzanne Sysko Clough, M.D., Chief Medical Officer and Co-Founder of WellDoc
- Ryan Sysko, Chief Executive Officer and Co-Founder of WellDoc
- Charlene Quinn, PhD, RN, Assistant Professor, Department of Epidemiology and Public Health, University of Maryland School of Medicine
- Kelly L. Close, President of Close Concerns, Inc.
- Sunday, June 26 at 6:45-8:00 p.m. in a late-breaking poster session presented by Dr. Charlene Quinn at the University of Maryland, the principal investigator in the clinical trial.
About WellDoc
WellDoc®, a healthcare company that develops technology solutions to improve chronic disease management outcomes and reduce healthcare costs, is focused on simplifying the way chronic diseases are managed through a collaborative, life-changing approach that breaks down the barriers of engagement and adherence by providing patients and their healthcare providers with real-time, actionable information. WellDoc has developed an industry-leading, technology-based solution that helps people with chronic diseases better manage their conditions. For more information, visit www.welldoc.com.
WellDoc’s flagship mHealth solution, the FDA-cleared DiabetesManager® System, provides automated, real-time clinical and behavioral coaching based on patient data. The software-based system supports adult type 2 patients and enables healthcare providers to configure specific parameters and extend their care beyond traditional office visits using mobile phones and the Internet.